In conclusion, our study further demonstrated that the development of irAEs with anti-PD-1/PD-L1 antibody therapy is related to better survival benefits in patients with NSCLC, especially endocrine, gastrointestinal, skin and low-grade irAEs. Here, CD274 is linked to non-small cell lung carcinoma.